Learn more about the latest research, findings and news from and about The Wanek Family Project for Type 1 Diabetes.
An innovative, first-of-its kind vaccine that uses a person’s own immune cells and vitamin D3 to treat type 1 diabetes is both safe and feasible, according to research published in The Lancet Diabetes and Endocrinology by City of Hope's Bart Roep, Ph.D.
Debbie Thurmond, Ph.D., studies proteins that have a long biological history. The family of SNARE proteins are an essential part of the body’s complex transport system, helping to regulate diverse biological processes. Thurmond investigates the role that certain members of that family play in metabolism — research that has the potential to result in new therapies for type 1 diabetes.
City of Hope researchers have found novel ways to classify type 1 diabetes patients for better treatment outcomes.
A new study characterizes how immune responses to type 1 diabetes (T1D) differ among individuals much more than previously thought. The study characterizes those differences in children with T1D, which represents an important first step toward personalized medicine for this patient population.
The family of SNARE proteins are an essential part of the body’s complex transport system, helping to regulate diverse biological processes. Thurmond investigates the role that certain members of that family play in metabolism — research that has the potential to result in new therapies for type 1 diabetes.
For nearly 50 years, scientists who have made major advances in the understanding and treatment of diabetes have called City of Hope home. Building on past milestones, as well as the institution’s acute understanding of the role of the immune system in cancer, investigators work on an integrated approach to type 1 diabetes with the support of The Wanek Family Project for Type 1 Diabetes.
They come from Amritsar, India; Beijing, China; Circle Pines, Minnesota … and lots of places in between. They are the next generation of diabetes researchers at City of Hope, bringing their diverse backgrounds, fresh perspectives, and youthful drive and enthusiasm to our mission to eliminate type 1 diabetes once and for all.
From longtime administrators to veteran faculty to next-generation researchers, so many diabetes specialists smile and mention the name Arthur D. Riggs when asked why they chose City of Hope.
Among the many talented diabetes researchers at City of Hope, there are several for whom the mission is deeply personal because they are type 1 diabetics themselves. Here are a few of their stories.
We debunk some of the misconceptions about type 1 diabetes in a conversation with Bart Roep, Ph.D., holder of City of Hope’s Chan Soon-Shiong Shapiro Distinguished Chair in Diabetes and professor and founding chair of the Department of Diabetes Immunology.
Many people struggle with both diabetes and cancer at the same time — none of this is random or coincidental. Rather, it's clear that, from biology to risk factors to treatment options, cancer and diabetes are intimately related in many ways.
City of Hope's Bart Roep, Ph.D., City of Hope’s Chan Soon-Shiong Shapiro Distinguished Chair in Diabetes, was invited to speak at the American Diabetes Association’s 79th Scientific Sessions, held June 7-11, 2019 in San Francisco. Roep and several City of Hope colleagues highlighted research successes and presented recent findings.
City of Hope scientists highlighted research successes and presented recent findings at the 2019 American Diabetes Association’s Scientific Sessions.
City of Hope — widely known as a center for cancer care and research — is also the home of one of the most influential diabetes research programs in the world.
More than 250 physicians and scientists from around the world attended the 2019 City of Hope Levine-Riggs Diabetes Research Symposium, held April 10 to 13 at The Westin Hotel in Pasadena, California.